Hemispherian
Private Company
Funding information not available
Overview
Hemispherian is pioneering a novel epigenetic approach to cancer therapy by developing small molecule activators of the TET2 enzyme. This 'first-in-class' mechanism aims to selectively restore the depleted DNA modification 5-hydroxymethylcytosine in cancer cells, inducing cytotoxicity while sparing normal tissues. The company's lead asset, GLIX1, is advancing into clinical trials for glioblastoma through a partnership with BioLineRx, with a broader pipeline, including GLIX5, in earlier stages. Backed by public Norwegian and European support, Hemispherian is targeting high-unmet-need oncology indications with a potentially safer and more effective therapeutic strategy.
Technology Platform
Small molecule activators of the TET2 enzyme, which restore depleted levels of the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) in cancer cells, triggering a selective DNA damage response and cell death.
Opportunities
Risk Factors
Competitive Landscape
Hemispherian is a pioneer in developing TET2 activators, a novel mechanism with few, if any, direct competitors. However, it competes indirectly in the crowded glioblastoma space with developers of other novel therapies (e.g., immunotherapies, targeted kinase inhibitors) and within the broader epigenetic drug market dominated by companies focused on histone deacetylase (HDAC) and bromodomain inhibitors.